½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1630508

¼¼°èÀÇ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå°ú °¢Á¾ ±â¼ú

Biomarkers: Technologies and Global Markets

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: BCC Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 165 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð´Â 2023³â 637¾ï ´Þ·¯, 2024³â 705¾ï ´Þ·¯¿¡¼­ ¿¹Ãø ±â°£ µ¿¾È CAGR 13.1%·Î ÃßÀÌÇÏ°í 2029³â ¸»¿¡´Â 1,302¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼Ò¸ðÇ° ºÎ¹®Àº 2024³â 408¾ï ´Þ·¯¿¡¼­ ¿¹Ãø ±â°£ µ¿¾È CAGR 12.7%·Î ÃßÀÌÇÏ°í, 2029³â ¸»¿¡´Â 740¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Àåºñ ºÎ¹®Àº 2024³â 175¾ï ´Þ·¯¿¡ À̸£°í, CAGR 14.1%·Î ÃßÀÌÇÏ°í 2029³â ¸»¿¡´Â 339¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º» º¸°í¼­¿¡¼­´Â ¼¼°è ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ±â¼ú°ú ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, ½ÃÀ念ÇâÀÎÀÚ ¹× ½ÃÀå ±âȸ ºÐ¼®, ¹ý±ÔÁ¦ ȯ°æ, ½ÅÈï±â¼ú ¹× ±â¼ú °³¹ß µ¿Çâ, ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø, °¢Á¾ ±¸ºÐ¡¤ Áö¿ªº° »ó¼¼ ºÐ¼®, °æÀï ±¸µµ, ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀ» Á¤¸®Çß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå Àü¸Á
  • Á¶»ç ¹üÀ§
  • ½ÃÀå °³¿ä

Á¦2Àå ½ÃÀå °³¿ä

  • °³¿ä
  • ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ºÐ·ù
  • ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¿¹
  • °¨¼ö¼º/¸®½ºÅ© ¹ÙÀÌ¿À¸¶Ä¿
  • Áø´Ü ¹ÙÀÌ¿À¸¶Ä¿
  • ¸ð´ÏÅ͸µ ¹ÙÀÌ¿À¸¶Ä¿
  • ¿¹ÈÄ ¹ÙÀÌ¿À¸¶Ä¿
  • ¿¹Ãø ¹ÙÀÌ¿À¸¶Ä¿
  • ¾à¿ªÇÐ(¹ÝÀÀ) ¹ÙÀÌ¿À ¸¶Ä¿
  • ¾ÈÀü¼º ¹ÙÀÌ¿À¸¶Ä¿
  • ´ëü ¹ÙÀÌ¿À¸¶Ä¿/¿£µåÆ÷ÀÎÆ®
  • ¹ß°ß, °ËÁõ, °ËÁõ
  • ¹ÙÀÌ¿À¸¶Ä¿ÀÇ Àû°Ý¼º
  • ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ÀÀ¿ë
  • Áø´Ü, Ä¡·á, Áúȯ ¸ð´ÏÅ͸µ
  • ÀǾàÇ°ÀÇ ¹ß°ß°ú °³¹ß
  • ÀÓ»ó½ÃÇè

Á¦3Àå ½ÃÀå ¿ªÇÐ

  • °³¿ä
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • º´ÀÇ ¹ß»ý·üÀÇ »ó½Â
  • ¿À¹Í½º¿Í À̹Ì¡ ±â¼úÀÇ Áøº¸
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ³ôÀº °³¹ß ºñ¿ë
  • ±â¼úÀ» °¡Áø ÀÎÀçÀÇ ¿ä°Ç
  • ½ÃÀå ±âȸ
  • ½ÅÈï ½ÃÀå
  • ¸ÂÃãÇü ÀÇ·á

Á¦4Àå ½Å±â¼ú°ú °³¹ß

  • °³¿ä
  • ½ÅÈï±â¼ú
  • À¯ÀüüÇÐ
  • ´Ü¹éÁúüÇÐ
  • ´ë»çüÇÐ
  • À̹Ì¡
  • ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º
  • ÀÓ»ó½ÃÇè
  • ÀÓ»ó½ÃÇè ºÐ¼® : Ä¡·á¿µ¿ªº°
  • ÀÓ»ó½ÃÇè ºÐ¼® : ¿¬±¸ »óȲº°
  • ÀÓ»ó½ÃÇè ºÐ¼® : ¿¬±¸ À¯Çüº°
  • ƯÇ㠺м®

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®

  • ½ÃÀå µ¿Çâ
  • ¼¼ºÐÈ­ÀÇ ³»¿ª
  • ¹ÙÀÌ¿À ¸¶Ä¿ : ¼¼°è ½ÃÀå
  • ½ÃÀå ºÐ¼® : Á¦Ç° À¯Çüº°
  • ¼Ò¸ðÇ°
  • ±â±â
  • ¼­ºñ½º
  • ¼ÒÇÁÆ®¿þ¾î
  • ½ÃÀå ºÐ¼® : ±â¼úº°
  • ´Ü¹éÁúüÇÐ
  • À¯ÀüüÇÐ
  • À̹Ì¡
  • ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º
  • ´ë»çüÇÐ
  • ½ÃÀå ºÐ¼® : Ä¡·á ¿µ¿ªº°
  • ¾Ï
  • ½ÉÀåÇ÷°ü ¹× ´ë»çÁúȯ
  • ½Å°æÅðÇ༺ Áúȯ
  • °¨¿°Áõ
  • ÀÚ°¡¸é¿ªÁúȯ
  • ±âŸ
  • ½ÃÀå ºÐ¼® : ÃÖÁ¾ »ç¿ëÀÚº°
  • º´¿ø ¹× Áø´Ü½ÇÇè½Ç
  • Çмú¿¬±¸±â°ü
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • CRO
  • Áö¸®Àû ³»¿ª
  • ½ÃÀå ºÐ¼® : Áö¿ªº°
  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ±âŸ Áö¿ª

Á¦6Àå °æÀï Á¤º¸

  • ¹ÙÀÌ¿À¸¶Ä¿ ¾÷°èÀÇ ±â¾÷ ¼øÀ§

Á¦7Àå ¹ÙÀÌ¿À¸¶Ä¿ÀÇ °¢Á¾ ±â¼ú°ú ¼¼°è ½ÃÀå¿¡¼­ÀÇ Áö¼Ó°¡´É¼º : ESGÀÇ °üÁ¡

  • ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå¿¡¼­ÀÇ Áö¼Ó°¡´É¼º
  • ESG À§Çè°ú µî±Þ: µ¥ÀÌÅÍ ÀÌÇØ
  • BCC¿¡ ÀÇÇÑ °ßÇØ

Á¦8Àå ºÎ·Ï

  • Á¶»ç ¹æ¹ý
  • Ãâó
  • ¾à¾î
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
  • ABBOTT
  • AGILENT TECHNOLOGIES INC.
  • BAYER AG
  • BD
  • BIO-RAD LABORATORIES INC.
  • BRUKER
  • DANAHER CORP.
  • F. HOFFMANN-LA ROCHE LTD.
  • FUJIFILM HOLDINGS CORP.
  • GE HEALTHCARE
  • ILLUMINA INC.
  • JEOL LTD.
  • KONINKLIJKE PHILIPS NV
  • PROMEGA CORP.
  • QIAGEN
  • REVVITY
  • SHIMADZU CORP.
  • SIEMENS HEALTHINEERS AG
  • THERMO FISHER SCIENTIFIC INC.
JHS 25.01.31

The global market for biomarkers was valued at $63.7 billion in 2023. This market is expected to grow from $70.5 billion in 2024 to $130.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 13.1% from 2024 through 2029.

The global market for biomarker consumables is expected to grow from $40.8 billion in 2024 to $74.0 billion by the end of 2029, at a CAGR of 12.7% from 2024 through 2029.

The global market for biomarker instruments is expected to grow from $17.5 billion in 2024 to $33.9 billion by the end of 2029, at a CAGR of 14.1% from 2024 through 2029.

Report Scope:

The scope of this report on the global market for biomarker technologies encompasses an analysis of the current landscape, including market size, growth trends and segmentation by product type, technology, therapeutic area and end user. The report breaks down the market into several product categories: instruments, consumables (such as reagents, kits and panels), services and software. It also segments the market by technology: genomics, proteomics, metabolomics, imaging and bioinformatics. It also examines the biomarker market across the therapeutic areas of cancer; cardiovascular, metabolic, infectious and neurodegenerative diseases; and autoimmune disorders. The end-user segments are academic institutions, pharmaceutical and biotechnology companies, clinical research organizations, hospitals and diagnostic centers.

By region, the analysis encompasses North America, Europe, Asia-Pacific, and the Rest of the World (RoW). The report also includes profiles of leading companies and highlights industry trends, major products, mergers and acquisitions, and other collaborations or partnerships.

Report Includes:

  • 34 data tables and 62 additional tables
  • An up-to-date overview of the global markets and technologies for biomarkers
  • Analysis of the global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
  • Evaluation of the size and revenue growth prospects, accompanied by a market share analysis by product type, technology, therapeutic area, end user, and region
  • Assessment of market dynamics such as drivers, restraints and opportunities
  • Coverage of major types of biomarkers and their use in clinical trial assessment, drug discovery and development, and therapeutics
  • Review of patents issued for biomarker technologies and deep dive of patent data by year, technology type, application, company, assignee and applicant country
  • A discussion on ESG challenges and practices in the industry
  • Assessment of the vendor landscape, including the market shares of key companies, their product portfolios and financial overviews
  • Information on recent mergers, acquisitions, expansions, collaborations, investments, divestments, product launches, and other strategic developments
  • Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Illumina Inc., Bio-Rad Laboratories Inc., and Agilent Technologies Inc.

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary

Chapter 2 Market Overview

  • Overview
  • Classification of Biomarkers
  • Examples of Biomarkers
  • Susceptibility/Risk Biomarkers
  • Diagnostic Biomarkers
  • Monitoring Biomarkers
  • Prognostic Biomarkers
  • Predictive Biomarkers
  • Pharmacodynamic (Response) Biomarkers
  • Safety Biomarkers
  • Surrogate Biomarkers/Endpoints
  • Discovery, Verification and Validation
  • Biomarker Qualification
  • Applications of Biomarkers
  • Diagnostics, Therapeutics and Disease Monitoring
  • Drug Discovery and Development
  • Clinical Trials

Chapter 3 Market Dynamics

  • Overview
  • Market Drivers
  • Rising Incidence of Diseases
  • Advances in Omics and Imaging Technologies
  • Market Restraints
  • High Development Costs
  • Requirement for Skilled Labor
  • Market Opportunities
  • Emerging Markets
  • Personalized Medicine

Chapter 4 Emerging Technologies and Developments

  • Overview
  • Emerging Technologies
  • Genomics
  • Proteomics
  • Metabolomics
  • Imaging
  • Bioinformatics
  • Clinical Trials
  • Clinical Trial Analysis, by Therapeutic Area
  • Clinical Trial Analysis, by Study Status
  • Clinical Trial Analysis, by Study Type
  • Patent Analysis

Chapter 5 Market Segmentation Analysis

  • Market Trends
  • Segmentation Breakdown
  • Biomarkers: Global Markets
  • Market Analysis by Product Type
  • Consumables
  • Instruments
  • Services
  • Software
  • Market Analysis by Technology
  • Proteomics
  • Genomics
  • Imaging
  • Bioinformatics
  • Metabolomics
  • Market Analysis by Therapeutic Area
  • Cancer
  • Cardiovascular and Metabolic Diseases
  • Neurodegenerative Diseases
  • Infectious Diseases
  • Autoimmune Diseases
  • Other Diseases
  • Market Analysis by End User
  • Hospitals and Diagnostic Labs
  • Academic and Research Institutes
  • Pharmaceutical and Biotech Companies
  • Contract Research Organizations
  • Geographic Breakdown
  • Market Analysis by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 6 Competitive Intelligence

  • Ranking of Companies in the Biomarker Industry

Chapter 7 Sustainability in Biomarkers Technologies and Global Markets: An ESG Perspective

  • Sustainability in the Biomarker Market
  • ESG Risks and Ratings: Understanding the Data
  • BCC Research Viewpoint

Chapter 8 Appendix

  • Methodology
  • Sources
  • Abbreviations
  • Company Profiles
  • ABBOTT
  • AGILENT TECHNOLOGIES INC.
  • BAYER AG
  • BD
  • BIO-RAD LABORATORIES INC.
  • BRUKER
  • DANAHER CORP.
  • F. HOFFMANN-LA ROCHE LTD.
  • FUJIFILM HOLDINGS CORP.
  • GE HEALTHCARE
  • ILLUMINA INC.
  • JEOL LTD.
  • KONINKLIJKE PHILIPS N.V.
  • PROMEGA CORP.
  • QIAGEN
  • REVVITY
  • SHIMADZU CORP.
  • SIEMENS HEALTHINEERS AG
  • THERMO FISHER SCIENTIFIC INC.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦